Metals in our minds: Therapeutic implications for neurodegenerative disorders

Lancet Neurology

Volumn 3, Issue 7, 2004, Pages 431-434

  Doraiswamy, P Murali ^a   Finefrock, Anne E ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; CLIOQUINOL; COPPER; IRON; NEUROMELANIN; ZINC;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BRAIN HEMORRHAGE; CATARACT; CORONARY ARTERY ATHEROSCLEROSIS; CREUTZFELDT JAKOB DISEASE; DIFFUSE LEWY BODY DISEASE; DOWN SYNDROME; DRUG BRAIN LEVEL; FAHR DISEASE; FRIEDREICH ATAXIA; HEMOCHROMATOSIS; HUMAN; HUNTINGTON CHOREA; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NEUROPATHOLOGY; PARKINSON DISEASE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; REVIEW; TARDIVE DYSKINESIA; WILSON DISEASE; ZINC BLOOD LEVEL;

EID: 2942729775     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(04)00809-9     Document Type: Short Survey

References (36)

1. Perry G, Sayre LM, Atwood CS, et al. The role of iron and copper in the aetiology of neurodegenerative disorders: therapeutic implications. CNS Drugs. 16:2002;339-352
2. Barnham KJ, Cherny RA, Cappai R, et al. Metal-protein attenuating compounds (MPACs) for the treatment of Alzheimer's disease. Drug Design Reviews Online. 1:2004;75-82
3. Finefrock A, Bush AI, Doraiswamy PM. Current status of metals as therapeutic targets in Alzheimer's disease. J Am Geriatr Soc. 51:2003;1143-1148
4. Pitchumoni S, Doraiswamy PM. Current status of antioxidant therapy for Alzheimer's disease. J Am Geriatr Soc. 46:1998;1566-1572
5. Levenson CW. Iron and Parkinson's disease: Chelators to the rescue? Nutr Rev. 61:2003;311-312
6. Brown DR, Wong BS, Hafiz F, Clive C, Haswell SJ, Jones IM. Normal prion protein has an activity like that of superoxide dismutase. Biochem J. 345:2000;767
7. Radisky DC, Babcock MC, Kaplan J. The yeast frataxin homologue mediates mitochondrial iron efflux. Evidence for a mitochondrial iron cycle. J Biol Chem. 274:1999;4497-4499
8. Estevez AG, Crow JP, Sampson JB, et al. Induction of nitric oxide-dependent apoptosis in motor neurons by zinc-deficient superoxide dismutase. Science. 286:1999;2498-2500
9. Campbell WG, Raskind MA, Gordon T, Shaw CM. Iron pigment in the brain of a man with tardive dyskinesia. Am J Psychiatry. 142:1985;364-365
10. Pandolfo M. Iron metabolism and mitochondrial abnormalities in Friedreich ataxia. Blood Cells Mol Dis. 29:2002;536-547
11. Drayer B, Burger P, Hurwitz B, Dawson D, Cain J. Reduced signal intensity on MR images of thalamus and putamen in multiple sclerosis: increased iron content? AJR Am J Roentgenol. 149:1987;357-363
12. Bush AI. The metallobiology of Alzheimer's disease. Trends Neurosci. 26:2003;207-214
13. Maynard CJ, Cappai R, Volitakis I, et al. Overexpression of Alzheimer's disease amyloid-beta opposes the age-dependent elevations of brain copper and iron. J Biol Chem. 277:2002;44670-44676
14. Opazo C, Huang X, Cherny RA, et al. Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2). J Biol Chem. 277:2002;40302-40308
15. Atwood CS, Scarpa RC, Huang X, et al. Characterization of copper interactions with Alzheimer amyloid β peptides. J Neurochem. 75:2000;1219-1233
16. Atwood CS, Huang X, Moir RD, Tanze RE, Bush AI. Role of free radicals and metal ions in the pathogenesis of Alzheimer's disease. Met Ions Biol Syst. 36:1999;309-364
17. Sparks D, Schreurs B. Trace amounts of copper in water induce b-amyloid plaques and learning deficits in a rabbit model of Alzheimer disease. Proc Natl Acad Sci USA. 100:2003;1065-1069
18. Phinney AL, Deisaldi B, Schmidt SD, et al. In vivo reduction of amyloid Aβ by a mutant copper transporter. Proc Natl Acad Sci USA. 100:2003;14193-14198
19. Bayer TA, Schafer S, Simons A, et al. Dietary Cu stabilizes brain SOD-1 activity and reduces amyoid Aβ production in APP23 transgenic mice. Proc Natl Acad Sci USA. 100:2003;14187-14192
20. Crapper McLachlan DR, Dalton AJ, Kruck TPA. Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet. 337:1991;1304-1308
21. Cuajungco MP, Faget KY, Huang X, Tanze RE, Bush AI. Metal chelation as a potential therapy for Alzheimer's disease. Ann NY Acad Sci. 920:2000;292-304
22. Cherny RA, Atwood CS, Xilinas ME, et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron. 30:2001;665-676
23. Regland B, Lehman W, Abedini I, et al. Treatment of Alzheimer's disease with clioquinol. Dement Geriatr Cogn Disord. 12:2001;408-414
24. Ritchie CW, Bush AI, Mackinnon A, et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol. 60:2003;1685-1691
25. Dominguez DI, DeStrooper B. Novel therapeutic strategies provide the real test for the amyloid hypothesis of Alzheimer disease. Trends Pharmacol Sci. 23:2002;324-333
26. Tabira T. Clioquinol's return: cautions from Japan. Science. 292:2001;2251-2252
27. Tsubaki T. Aetiological and clinical study on subacute myelo-optico-neuropathy (SMON). Nippon Naika Gakkai Zasshi. 63:1974;1-17
28. Tateishi J. Subacute myelo-optico-neuropathy: clioquinol intoxication in humans and animals. Neuropathology ; (suppl). 20:2000;S20-24
29. Arbiser JL, Kraeft SK, van Leeuwen R, et al. Clioquinol-zinc chelate: a candidate causative agent of subacute myelo-optic neuropathy. Mol Med. 4:1998;665-670
30. Konagaya M, Matsumoto A, Takase S, et al. Clinical analysis of longstanding subacute myelo-optico-neuropathy: sequelae of clioquinol at 32 years after its ban. J Neurol Sci. 218:2004;85-90
31. Wadia NH. SMON as seen from Bombay. Acta Neurol Scand Suppl. 100:1984;159-164
32. Jellinger KA. The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease. Drugs Aging. 14:1999;115-140
33. Goldstein LE, Leopold MC, Huang X, et al. 3-hydroxykynurenine and 3-hydroxyanthranilic acid generate hydrogen peroxide and promote alpha-crystallin cross-linking by metal ion reduction. Biochemistry. 39:2000;7266-7275
34. Kaur D, Yantiri F, Rajagopalan S, et al. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron. 37:2003;899-909
35. Bush AI. Metals and neuroscience. Curr Opin Chem Biol. 4:2000;184-191
36. Hilditch-Maguire P, Trettel F, Passani LA, et al. Huntingtin: an iron-regulated protein essential for normal nuclear and perinuclear organelles. Hum Mol Genet. 9:2000;2789-2797